Payment overview · 2025
General Payments
$1,005.57
50 reported records · 15 companies
Healthcare provider profile · identity verified
Sonya Fleming, NP
Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine · HIGH POINT, NC · NPI 1326750514
Verified facts
What the public records show
CMS Open Payments records show Sonya Fleming, NP received $1,005.57 in general payments during 2025 across 50 reported records.
ABBVIE INC. accounted for 40.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $411.41 | 40.9% | 27 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $210.06 | 20.9% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $45.17 | 4.5% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $43.39 | 4.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.32 | 4.2% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $36.79 | 3.7% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.69 | 3.2% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $32.36 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.59 | 2.9% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $24.91 | 2.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.07 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.32 | 2.0% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $18.59 | 1.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.85 | 1.8% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.05 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,005.57 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $265.74 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $194.63 | 18 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $117.98 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $110.81 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $92.08 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $45.17 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $43.39 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $32.69 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $32.36 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 458 | 97 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 456 | 98 |
| Oxycodone Hcl | Oxycodone Hcl | 416 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 230 | 82 |
| Gabapentin | Gabapentin | 224 | 70 |
| Alprazolam | Alprazolam | 207 | 34 |
| Clonazepam | Clonazepam | 178 | 35 |
| Lisinopril | Lisinopril | 160 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 159 | 56 |
| Omeprazole | Omeprazole | 156 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 31 |
| Prednisone | Prednisone | 99 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 97 | 34 |
| Naloxone Hcl | Naloxone Hcl | 93 | 65 |
| Pregabalin | Pregabalin | 93 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 26 |
| Tramadol Hcl | Tramadol Hcl | 80 | 27 |
| Amoxicillin | Amoxicillin | 77 | 60 |
| Metformin Hcl | Metformin Hcl | 73 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 17 |
| Potassium Chloride | Potassium Chloride | 67 | 17 |
| Furosemide | Furosemide | 65 | 26 |
| Ozempic | Semaglutide | 65 | 15 |
| Mounjaro | Tirzepatide | 61 | 19 |
| Farxiga | Dapagliflozin Propanediol | 57 | 16 |
| Montelukast Sodium | Montelukast Sodium | 56 | 21 |
| Fluconazole | Fluconazole | 52 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 12 |
| Famotidine | Famotidine | 50 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 14 |
| Losartan Potassium | Losartan Potassium | 46 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 14 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Meloxicam | Meloxicam | 37 | 11 |
| Telmisartan | Telmisartan | 37 | 13 |
| Trazodone Hcl | Trazodone Hcl | 36 | 15 |
| Azithromycin | Azithromycin | 35 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | 11 |
| Simvastatin | Simvastatin | 33 | 11 |
| Eliquis | Apixaban | 32 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | 11 |
| Carvedilol | Carvedilol | 31 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | 26 |
| Lorazepam | Lorazepam | 30 | suppressed |
| Linzess | Linaclotide | 29 | 12 |
| Sertraline Hcl | Sertraline Hcl | 29 | 11 |
| Atrovent Hfa | Ipratropium Bromide | 28 | 18 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Xtampza Er | Oxycodone Myristate | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 25 |
| Atenolol | Atenolol | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Topiramate | Topiramate | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 13 |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,005.57 · 50 records | ABBVIE INC. | BREZTRI, Belbuca, FARXIGA, GEMTESA, Hillrom - Carnation Ambulatory Monitor, IBSRELA, JOURNAVX, Korlym, MOUNJARO, Ozempic, QULIPTA, UBRELVY, VOQUEZNA, VRAYLAR, WAKIX, Wegovy, YUPELRI, ZENPEP, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error